» Articles » PMID: 16621364

High Throughput Microsomal Stability Assay for Insoluble Compounds

Overview
Journal Int J Pharm
Specialties Chemistry
Pharmacology
Date 2006 Apr 20
PMID 16621364
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

High throughput metabolic stability assays are widely implemented in drug discovery to guide structural modification, predict in vivo performance, develop structure-metabolic stability relationships, and triage compounds for in vivo animal studies. However, these methods are often developed and validated using commercial drugs. Many drug discovery compounds differ from commercial drugs, with many having high lipophilicity, high molecular weight and low solubility. The impact of very low solubility on metabolic stability assay results was explored. Two metabolic stability assays, the 'aqueous dilution method' and the 'cosolvent method, were compared. For commercial drugs and most discovery compounds having reasonable drug-like properties, the two methods gave comparable results. For highly lipophilic, insoluble drug discovery compounds, the 'aqueous dilution method' gave artificially higher stability results. The cosolvent method performs compound dilutions in solutions with higher organic solvent content and adds solutions directly to microsomes to assist with solubilization, minimize precipitation and reduce non-specific binding to plastics. This method is more applicable in drug discovery where compounds of a wide range of solubility are studied.

Citing Articles

Early Preclinical Studies of Ergosterol Peroxide and Biological Evaluation of Its Derivatives.

Ling T, Arroyo-Cruz L, Smither W, Seighman E, Martinez-Montemayor M, Rivas F ACS Omega. 2024; 9(35):37117-37127.

PMID: 39246459 PMC: 11375702. DOI: 10.1021/acsomega.4c04350.


The First In Vivo Study Shows That Gyrophoric Acid Changes Behavior of Healthy Laboratory Rats.

Simko P, Leskanicova A, Suvakova-Nunhart M, Koval J, Zidekova N, Karasova M Int J Mol Sci. 2024; 25(12).

PMID: 38928485 PMC: 11203575. DOI: 10.3390/ijms25126782.


Inhibiting spinal cord-specific hsp90 isoforms reveals a novel strategy to improve the therapeutic index of opioid treatment.

Duron D, Tanguturi P, Campbell C, Chou K, Bejarano P, Gabriel K Sci Rep. 2024; 14(1):14715.

PMID: 38926482 PMC: 11208559. DOI: 10.1038/s41598-024-65637-6.


Preclinical evaluation of proteolytic targeting of LCK as a therapeutic approach in T cell acute lymphoblastic leukemia.

Hu J, Jarusiewicz J, Du G, Nishiguchi G, Yoshimura S, Panetta J Sci Transl Med. 2022; 14(659):eabo5228.

PMID: 36001679 PMC: 9730446. DOI: 10.1126/scitranslmed.abo5228.


Biochemical Properties of Atranorin-Induced Behavioral and Systematic Changes of Laboratory Rats.

Simko P, Leskanicova A, Suvakova M, Blicharova A, Karasova M, Goga M Life (Basel). 2022; 12(7).

PMID: 35888178 PMC: 9316313. DOI: 10.3390/life12071090.